Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
This is a multi-center, non-randomized and open-label phase I/IIa clinical study to evaluate the safety, tolerability, and efficacy of ICP-490 in patients with relapsed or refractory non-hodgkin lymphoma.
Relapsed or Refractory Non-Hodgkin Lymphoma
DRUG: ICP-490
Incidence, type, and severity of adverse events (AEs) as judged according to NCI-CTCAE V5.0, Through study completion，an average of 3 years|Incidence, type, and severity of dose-limiting toxicities (DLTs);, Through study completion，an average of 3 years|Recommended Phase 2 Doses（RP2Ds） and/or maximum tolerated doses（MTDs）., Through study completion，an average of 3 years|ORR assessed according to the Lugano criteria (Cheson 2014)., Through study completion，an average of 3 years
PK parameters: maximum concentration (Cmax), Through study completion，an average of 3 years|PK parameters: time to maximum concentration (Tmax), Through study completion，an average of 3 years|PK parameters: half-life (T1/2), Through study completion，an average of 3 years|PK parameters: area under the concentration-time curve (AUC0-∞ and AUC0-t), Through study completion，an average of 3 years|PK parameters: apparent clearance (CL/F), Through study completion，an average of 3 years|PK parameters: apparent volume of distribution during terminal phase (Vz/F), Through study completion，an average of 3 years|PK parameters:Steady-state PK parameters, Through study completion，an average of 3 years|The overall response rate (ORR) assessed according to the Lugano criteria (Cheson 2014)., Through study completion，an average of 3 years|Complete response rate (CRR) assessed according to the Lugano criteria (Cheson 2014)., Through study completion，an average of 3 years|Time to response (TTR) assessed according to the Lugano criteria (Cheson 2014)., Through study completion，an average of 3 years|Duration of response (DOR) assessed according to the Lugano criteria (Cheson 2014)., Through study completion，an average of 3 years|Progression-free survival (PFS) assessed according to the Lugano criteria (Cheson 2014)., Through study completion，an average of 3 years|Overall survival (OS), Through study completion，an average of 3 years
This is a multi-center, non-randomized and open-label phase I/IIa clinical study to evaluate the safety, tolerability, and efficacy of ICP-490 in patients with relapsed or refractory non-hodgkin lymphoma.